Awards for “TEVA PHARMACEUTICALS USA, INC.”
25 awards on this page · sorted by amount · page 2
| Award ID | Recipient | Awarding agency | Amount | Start | End | NAICS | Description |
|---|---|---|---|---|---|---|---|
| SPE2DP26F5466 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $1.03M | 2026-05-11 | 2026-05-19 | 325412 | 8512097239!ADENOVIRUS TYPE 4 A |
| SPE2DP26F4633 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $1.03M | 2026-04-15 | 2026-04-29 | 325412 | 8512041924!ADENOVIRUS TYPE 4 A |
| SPE2DP23F0887 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $1.03M | 2022-12-06 | 2022-12-20 | 325412 | 8509568637!ADENOVIRUS TYPE 4 A |
| SPE2DP23F0884 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $1.03M | 2022-12-06 | 2022-12-20 | 325412 | 8509567884!ADENOVIRUS TYPE 4 A |
| SPE2DP25F6739 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $990.94K | 2025-05-12 | 2025-05-20 | 325412 | 8511369471!ADENOVIRUS TYPE 4 A |
| SPE2DP25F5523 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $990.94K | 2025-04-07 | 2025-04-29 | 325412 | 8511296118!ADENOVIRUS TYPE 4 A |
| SPE2DP25F4415 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $990.94K | 2025-03-06 | 2025-03-25 | 325412 | 8511229343!ADENOVIRUS TYPE 4 A |
| SPE2DP21F4301 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $988.24K | 2021-06-08 | 2021-06-22 | 325412 | 8508275916!ADENOVIRUS TYPE 4 A |
| SPE2DP24F2818 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $952.83K | 2024-02-22 | 2024-02-27 | 325412 | 8510462163!ADENOVIRUS TYPE 4 A |
| SPE2DP20F7223 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $950.23K | 2020-09-21 | 2020-09-29 | 325412 | 8507666471!ADENOVIRUS TYPE 4 A |
| SPE2DP20F6213 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $950.23K | 2020-07-22 | 2020-07-28 | 325412 | 8507538016!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5006 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $950.23K | 2020-05-21 | 2020-05-28 | 325412 | 8507395371!ADENOVIRUS TYPE 4 A |
| SPE2DP20F2432 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $950.23K | 2020-02-07 | 2020-02-11 | 325412 | 8507153556!ADENOVIRUS TYPE 4 A |
| W81XWH20C0100 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $928.81K | 2020-08-05 | 2021-08-04 | 325412 | ADENOVIRUS VACCINE EFFICIENCY STUDY. |
| SPE2DP24F1237 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $916.18K | 2023-12-14 | 2023-12-19 | 325412 | 8510325476!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5671 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $916.18K | 2023-08-22 | 2023-08-29 | 325412 | 8510093039!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5011 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $916.18K | 2023-07-18 | 2023-07-25 | 325412 | 8510016965!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5005 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $916.18K | 2023-07-18 | 2023-07-25 | 325412 | 8510016515!ADENOVIRUS TYPE 4 A |
| SPE2DP23F4565 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $916.18K | 2023-06-20 | 2023-06-27 | 325412 | 8509963743!ADENOVIRUS TYPE 4 A |
| SPE2DP21F6140 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $847.06K | 2021-09-09 | 2021-09-28 | 325412 | 8508509762!ADENOVIRUS TYPE 4 A |
| SPE2DP21F5486 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $847.06K | 2021-08-11 | 2021-08-24 | 325412 | 8508432581!ADENOVIRUS TYPE 4 A |
| SPE2DP21F3780 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $847.06K | 2021-05-06 | 2021-05-25 | 325412 | 8508191759!ADENOVIRUS TYPE 4 A |
| SPE2DP25F109W | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $825.78K | 2025-09-08 | 2025-09-23 | 325412 | 8511624235!ADENOVIRUS TYPE 4 A |
| SPE2DP25F109V | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $825.78K | 2025-09-08 | 2025-09-23 | 325412 | 8511624231!ADENOVIRUS TYPE 4 A |
| SPE2DP25F109S | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $825.78K | 2025-09-08 | 2025-09-23 | 325412 | 8511624191!ADENOVIRUS TYPE 4 A |